Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer

Journal of Surgical Oncology

Volumn 103, Issue 3, 2011, Pages 283-289

  Liu, Yan Long ^a   Yang, Yan Mei ^a   Xu, Hui ^a   Dong, Xin Shu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; Liver metastasis; USP22

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 22; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; LIVER METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ADULT; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; THIOLESTER HYDROLASES;

EID: 79952030196     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21802     Document Type: Article

References (25)

1. Huerta E, Grey N: Cancer control opportunities in low- and middle-income countries. CA Cancer J Clin 2007;57:72-74. (Pubitemid 46535707)
2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487.
4. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521. (Pubitemid 40814659)
5. Glinsky GV: "Stemness" genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. J Clin Oncol 2008;26:2846-2853.
6. Glinsky GV: Genomic models of metastatic cancer: Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb group (PcG) protein chromatin silencing pathway. Cell Cycle 2006;5:1208-1216.
7. Berezovska OP: Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5:1886-1901.
8. Zhao Y, Lang G, Ito S, et al.: A TFTC/STAGA module mediates Histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 2008;29:92-101.
9. Zhang XY, Varthi M, Sykes SM, et al.: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008;29:102-111.
10. Baek KH: Conjugation and deconjugation of ubiquitin regulating the destiny of proteins. Exp Mol Med 2003;35:1-7.
11. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002;82:373-428. (Pubitemid 34654457)
12. Ovaa H, Kessler BM, Rolén U, et al.: Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 2004;101:2253-2258. (Pubitemid 38269298)
13. Gilchrist CA, Baker RT: Characterization of the ubiquitin-specific protease activity of the mouse/human Unp/Unph oncoprotein. Biochim Biophys Acta 2000;1481:297-309.
14. Janssen JW, Schleithoff L, Bartram CR, et al.: An oncogenic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 1998;16:1767-1772. (Pubitemid 28175058)
15. Gray DA, Inazawa J, Gupta K, et al.: Elevated expression of Unph, a proto-oncogene at 3p21.3, in human lung tumors. Oncogene 1995;10:2179-2183.
16. Li M, Chen D, Shiloh A, et al.: Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-653. (Pubitemid 34406767)
17. Li Z, Wang D, Na X, et al.: Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun 2002;294:700-709. (Pubitemid 34694069)
18. Jensen DE, Proctor M, Marquis ST, et al.: BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-1112. (Pubitemid 28127509)
19. Lee HJ, Kim MS, Shin JM, et al.: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Exp Patterns 2006;6:277-284.
20. Glinsky GV: Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cell Rev 2007;3:79-93.
21. Pijnappel WW, Timmers HT: Dubbing SAGA unveils new epigenetic crosstalk. Mol Cell 2008;29:152-154. (Pubitemid 351181281)
22. Zhang XY, Pfeiffer HK, Thorne AW, et al.: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the Polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 2008;7:1522-1524. (Pubitemid 351881314)
23. Wang H, Wang L, Erdjument-Bromage H, et al.: Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004;431:873-878. (Pubitemid 39434086)
24. Henry KW, Wyce A, Lo WS, et al.: Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 2003;17:2648-2663. (Pubitemid 37363070)
25. Berger SL: The complex language of chromatin regulation during transcription. Nature 2007;447:407-412.